Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

OncoTargets and Therapy
Felix A MensahLocke J Bryan

Abstract

The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment alternatives across a range of malignancy types. Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. The advent of PI3K-specific small molecular inhibitors has led to increased efficacy with avoidance of an excessive toxicity profile. Key enzymes of the PI3K pathway exhibit differing expression in tissue types and roles in tumor pathogenesis. Copanlisib (BAY 80-6946) is a pan-specific PI3K small molecule inhibitor for four key isoforms with increased activity against PI3Kα and PI3Kδ, both important in B-cell malignancies. Follicular lymphoma is one of the most common indolent B-cell non-Hodgkin lymphomas worldwide. Follicular lymphoma like other indolent B-cell non-Hodgkin lymphomas is beleaguered by high relapse rates and the need for subsequent therapy options. Based on efficacy and a limited toxicity profile, copanlisib received accelerated US Food a...Continue Reading

Citations

Mar 1, 2019·Biomolecules·Michelle S MillerSandra B Gabelli
Mar 21, 2020·Clinical Journal of Oncology Nursing·Barbara B Rogers
Jun 25, 2020·Expert Review of Clinical Pharmacology·Massimo MagagnoliArmando Santoro
Dec 21, 2018·International Journal of Molecular Sciences·Angelo MaffeiDaniela Carnevale
Jan 24, 2019·International Journal of Molecular Sciences·Vanessa Edna SanchezYong-Mi Kim
May 2, 2020·Current Treatment Options in Oncology·Vladimir Sapon-CousineauSarit Assouline
Sep 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Olivia G FaheyElizabeth N Dow-Hillgartner
Jun 12, 2020·Clinical Microbiology Reviews·Joshua S DavisMichael Boyle
Nov 3, 2020·Leukemia & Lymphoma·Philipp Berning, Georg Lenz
Mar 10, 2021·Targeted Oncology·Javier MunozLoretta J Nastoupil
Mar 7, 2021·Cancers·Chiara PediconeWilliam G Kerr
Jan 28, 2022·Expert Opinion on Therapeutic Targets·Ahsan Anjoom Sunil, Tom Skaria

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Clinical Trials Mentioned

NCT01660451
NCT02369016
NCT02367040
NCT02626455

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.